ARS Pharmaceuticals, Inc.
SPRY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $60 | $52 | $40 | $51 |
| Short-Term Investments | $229 | $189 | $236 | $263 |
| Receivables | $36 | $26 | $10 | $9 |
| Inventory | $8 | $9 | $7 | $5 |
| Other Curr. Assets | $6 | $6 | $11 | $6 |
| Total Curr. Assets | $339 | $281 | $304 | $334 |
| Property Plant & Equip (Net) | $3 | $3 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $15 | $13 | $7 | $8 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $17 | $16 | $15 | $8 |
| Total NC Assets | $34 | $32 | $23 | $17 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $373 | $313 | $327 | $351 |
| Liabilities | – | – | – | – |
| Payables | $8 | $16 | $4 | $10 |
| Short-Term Debt | $1 | $1 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $1 | $1 | $1 |
| Other Curr. Liab. | $42 | $29 | $23 | $13 |
| Total Curr. Liab. | $51 | $46 | $28 | $23 |
| LT Debt | $1 | $1 | $0 | $0 |
| Deferred Rev, NC | $0 | $1 | $1 | $2 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $173 | $73 | $69 | $69 |
| Total NC Liab. | $174 | $76 | $71 | $71 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $2 | $0 | $0 |
| Total Liabilities | $225 | $121 | $98 | $94 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$253 | -$202 | -$157 | -$123 |
| AOCI | -$0 | -$0 | $0 | $0 |
| Other Equity | $401 | $394 | $386 | $380 |
| Total Equity | $148 | $192 | $229 | $257 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $373 | $313 | $327 | $351 |
| Net Debt | -$58 | -$50 | -$40 | -$51 |